Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background: Sarcopenia, characterized by low muscle mass, associates with mortality in patients with cirrhosis. Skeletal muscle area in a single computed tomography image at the level of the third lumbar vertebrate (L3) is a valid representative of whole body muscle mass. Controversy remains regarding applicability of psoas muscle to identify patients at greater risk of mortality. We aimed to determine psoas muscle index (PMI) association with skeletal muscle index (SMI) and to evaluate the capacity of PMI to predict liver transplant waitlist mortality. Methods: We evaluated listed adult patients with cirrhosis from 2012 to 2013 at four North American liver transplant centres. From L3 computed tomography images within 3 months of listing, we determined SMI and PMI expressed by cm 2/m 2. Low SMI was defined as SMI <39 cm 2/m 2 in women and <50 cm 2/m 2 in men as published by us earlier. Cut‐offs for PMI to predict mortality were established using a receiver‐operating characteristic analysis. Mortality predictors were determined using competing‐risk analysis with reported results as subdistribution hazard ratios (sHRs). Results: Of 353 waitlist candidates, 68% were men, mean age 56 ± 9 years, and Model for End‐stage Liver Disease of 16 ± 8 points. Low SMI was present more frequently in men than women (51 vs. 36%, P = 0.02). Moderately strong correlation between SMI and PMI was observed (r > 0.7, P < 0.001). Low PMI (males < 5.1 cm 2/m 2; females < 4.3 cm 2/m 2) yielded poor and moderate concordance with low SMI in men and women, respectively (Kappa coefficient 0.31 and 0.63). SMI (39 ± 9 vs. 43 ± 7 cm 2/m 2; P = 0.009) and PMI (4.4 ± 1.3 vs. 5.2 ± 1.1 cm 2/m 2; P = 0.001) were lower in women who died and/or were delisted (compared with non‐deceased patients) whereas men who died and/or were delisted had only lower SMI (47 ± 7 vs. 51 ± 9 cm 2/m 2; P = 0.003), but not PMI compared with non‐deceased patients. In women, both SMI (sHR 0.94, P = 0.048) and PMI (sHR 0.58, P = 0.002) were predictors of mortality, while in men, SMI was significant (sHR 0.95, P = 0.001) and PMI showed a trend to be (sHR 0.85, P = 0.09) associated with mortality. Overall, 104 patients (29%) were misclassified between SMI and PMI categories. Using PMI cut‐offs, 66% and 28% of low SMI men and women, who have a higher risk of mortality, were incorrectly classified as low risk. Conclusions: Skeletal muscle index is a more complete and robust measurement than PMI, especially in men with cirrhosis. Low PMI identifies an incomplete subset of patients at increased risk of mortality indicated by low SMI. Given the poor performance of PMI, SMI should not be substituted by PMI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanley, J. A., & McNeil, B. J. (1983) · Radiology · doi:10.1148/radiology.148.3.6878708 · Cited by 7,016
Introduction to the Analysis of Survival Data in the Presence of Competing Risks
Austin, P. C., Lee, D. S., & Fine, J. P. (2016) · Circulation · doi:10.1161/circulationaha.115.017719 · Cited by 2,653 · cited 1×
“Applying competing-risk analysis, rather than conventional survival analysis, is a more robust approach in the presence of competing event.(38) Patients were included from four North American LT centres with”
MethodMourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224 · cited 1×
“level of the third lumbar vertebrate (L3) is a reliable and valid representative of whole body muscle mass.(8,9) Besides SMI, individual muscle measurements, i.”
BackgroundShen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M.-P., Albu, J., Heymsfield, S. B., & Heshka, S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00744.2004 · Cited by 1,692 · cited 2×
“level of the third lumbar vertebrate (L3) is a reliable and valid representative of whole body muscle mass.(8,9) Besides SMI, individual muscle measurements, i.”
BackgroundMethodMitsiopoulos, N., Baumgartner, R. N., Heymsfield, S. B., Lyons, W., Gallagher, D., & Ross, R. (1998) · Journal of Applied Physiology · doi:10.1152/jappl.1998.85.1.115 · Cited by 1,522
Montano-Loza, A. J., Angulo, P., Meza-Junco, J., Prado, C. M. M., Sawyer, M. B., Beaumont, C., Esfandiari, N., Ma, M., & Baracos, V. E. (2016) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12039 · Cited by 512
A multicenter study to define sarcopenia in patients with end-stage liver disease
Carey, E. J., Lai, J. C., Wang, C. W., Dasarathy, S., Lobach, I., Montano‐Loza, A. J., Dunn, M. A., & for the Fitness, L. E. (2017) · Liver Transplantation · doi:10.1002/lt.24750 · Cited by 498
Self-citationvan Vugt, J. L. A., Levolger, S., de Bruin, R. W. F., van Rosmalen, J., Metselaar, H. J., & IJzermans, J. N. M. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13732 · Cited by 361
van Vugt, J. L. A., Levolger, S., Gharbharan, A., Koek, M., Niessen, W. J., Burger, J. W. A., Willemsen, S. P., de Bruin, R. W. F., & IJzermans, J. N. M. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12158 · Cited by 217
van Vugt, J. L. A., Alferink, L. J. M., Buettner, S., Gaspersz, M. P., Bot, D., Darwish Murad, S., Feshtali, S., van Ooijen, P. M. A., Polak, W. G., Porte, R. J., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.030 · Cited by 208 · cited 1×
“Although sarcopenia is not a current criterion for expedited LT, giving some priority to those patients with sarcopenia may help to decrease mortality in a subgroup of patients with cirrhosis.(3,29) Sarcopenia is one of the major manifestations of protein-energy malnutrition in cachexiaassociated diseases, and to prev…”
Background
Cited by
Lai, J. C., Tandon, P., Bernal, W., Tapper, E. B., Ekong, U., Dasarathy, S., & Carey, E. J. (2021) · Hepatology · doi:10.1002/hep.32049 · Cited by 742
“(133) Quantitative morphomics by MRI is less well studied in patients with cirrhosis but offers the same theoretical advantages as CT-based measures of muscle mass (and is often more costly and less readily available in resource-limited settings).”
BackgroundSelf-citationEffect of sarcopenia on survival in patients with cirrhosis: A meta-analysis
Tantai, X., Liu, Y., Yeo, Y. H., Praktiknjo, M., Mauro, E., Hamaguchi, Y., Engelmann, C., Zhang, P., Jeong, J. Y., van Vugt, J. L. A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.006 · Cited by 426
Sarcopenia and frailty in decompensated cirrhosis
Tandon, P., Montano-Loza, A. J., Lai, J. C., Dasarathy, S., & Merli, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.025 · Cited by 408
Self-citationSarcopenia in cirrhosis: from pathogenesis to interventions
Ebadi, M., Bhanji, R. A., Mazurak, V. C., & Montano-Loza, A. J. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01605-6 · Cited by 292
Self-citationNonalcoholic fatty liver disease and sarcopenia: Where do we stand?
Mikolasevic, I., Pavic, T., Filipec Kanizaj, T., Bender, D. V., Domislovic, V., & Krznaric, Z. (2020) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2020/8859719 · Cited by 30
Osteosarcopenia in NAFLD/MAFLD: an underappreciated clinical problem in chronic liver disease
Musio, A., Perazza, F., Leoni, L., Stefanini, B., Dajti, E., Menozzi, R., Petroni, M. L., Colecchia, A., & Ravaioli, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087517 · Cited by 26
Metadata
- Authors
- Ebadi, M., Wang, C. W., Lai, J. C., Dasarathy, S., Kappus, M. R., Dunn, M. A., Carey, E. J., Montano‐Loza, A. J., & From the Fitness, L. E.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2018-09-29
- Volume
- 9
- Issue
- 6
- Pages
- 1053-1062
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W2893179068
- Cited by
- 142
- References
- 12
- FWCI
- 9.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.